Optimizing the Clinical Impact of CAR-T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia: Looking Back While Moving Forward

Optimizing the Clinical Impact of CAR-T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia: Looking Back While Moving Forward

Chimeric antigen receptor T-cell (CAR-T) therapy has been successful in creating extraordinary clinical outcomes in the treatment of hematologic malignancies including relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). With several FDA approvals, CAR-T therapy is recognized as...

Full description

Bibliographic Details
Main Authors:	Pouya Safarzadeh Kozani, Pooria Safarzadeh Kozani, Fatemeh Rahbarizadeh
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-10-01
Series:	Frontiers in Immunology
Subjects:	chimeric antigen receptor cytokine release syndrome neurotoxicity acute lymphoblastic leukemia adoptive cell therapy cancer immunotherapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2021.765097/full

Similar Items

Strategies for Dodging the Obstacles in CAR T Cell Therapy
by: Pooria Safarzadeh Kozani, et al.
Published: (2021-04-01)

Novel antigens of CAR T cell therapy: New roads; old destination
by: Pooria Safarzadeh Kozani, et al.
Published: (2021-07-01)

CAR-T cell therapy in T-cell malignancies: Is success a low-hanging fruit?
by: Pouya Safarzadeh Kozani, et al.
Published: (2021-10-01)

Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero?
by: Pouya Safarzadeh Kozani, et al.
Published: (2022-05-01)

CAR-T cell immunotherapy for ovarian cancer: hushing the silent killer
by: Fatemeh Nasiri, et al.
Published: (2023-12-01)

T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts
by: Fatemeh Nasiri, et al.
Published: (2023-02-01)

Nanobody-based CAR-T cells for cancer immunotherapy
by: Pouya Safarzadeh Kozani, et al.
Published: (2022-04-01)

CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil
by: Fatemeh Nasiri, et al.
Published: (2022-11-01)

Characterization of novel CD19-specific VHHs isolated from a camelid immune library by phage display
by: Mahmoud Ganji, et al.
Published: (2023-12-01)

AS1411-functionalized delivery nanosystems for targeted cancer therapy
by: Pooria Safarzadeh Kozani, et al.
Published: (2021-04-01)

Marine Bacteria versus Microalgae: Who Is the Best for Biotechnological Production of Bioactive Compounds with Antioxidant Properties and Other Biological Applications?
by: Masoud Hamidi, et al.
Published: (2019-12-01)

Directional capacity of human mesenchymal stem cells to support hematopoietic stem cell proliferation in vitro
by: Boroojerdi, Mohadese Hashem, et al.
Published: (2022)

Site-specific transgene integration in chimeric antigen receptor (CAR) T cell therapies
by: Hamed Dabiri, et al.
Published: (2023-07-01)

New cell sources for CAR-based immunotherapy
by: Marzieh Mazinani, et al.
Published: (2023-05-01)

CAR-T cell potency: from structural elements to vector backbone components
by: Marzieh Mazinani, et al.
Published: (2022-09-01)

CAR T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia
by: Khalil Saleh, et al.
Published: (2023-10-01)

Spinoculation and retronectin highly enhance the gene transduction efficiency of Mucin-1-specific chimeric antigen receptor (CAR) in human primary T cells
by: Alireza Rajabzadeh, et al.
Published: (2021-11-01)

Timing of Tocilizumab Administration Under the Guidance of IL-6 in CAR-T Therapy for R/R Acute Lymphoblastic Leukemia
by: Yinqiang Zhang, et al.
Published: (2022-06-01)

Novel pathophysiological insights into CAR-T cell associated neurotoxicity
by: Vassilis Genoud, et al.
Published: (2023-03-01)

Neurological management and work-up of neurotoxicity associated with CAR T cell therapy
by: Nora Möhn, et al.
Published: (2022-01-01)

Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy
by: Zhenguang Wang, et al.
Published: (2018-01-01)

Neurotoxicity Associated with Treatment of Acute Lymphoblastic Leukemia Chemotherapy and Immunotherapy
by: Patrycja Śliwa-Tytko, et al.
Published: (2022-05-01)

CAR T-Cells in Acute Lymphoblastic Leukemia: Current Status and Future Prospects
by: Abdulrahman H. Almaeen, et al.
Published: (2023-10-01)

Cardiac involvement in a patient with B-cell lymphoblastic lymphoma/acute lymphoblastic leukemia and a history of allogeneic hematopoietic stem cell transplantation and CAR T-cell therapy: A case report
by: Yigeng Cao, et al.
Published: (2023-01-01)

Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy
by: Lorenzo Lindo, et al.
Published: (2021-02-01)

Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD‐19 chimeric antigen receptor T‐cell therapy
by: Francesco Paolo Tambaro, et al.
Published: (2020-09-01)

CAR T Cell Therapy: A Versatile Living Drug
by: Rodrigo C. De Marco, et al.
Published: (2023-03-01)

Successful stem cell transplantation after nelarabine, pegylated asparaginase, vincristine, doxorubicin, and prednisone in refractory early T-cell precursor acute lymphoblastic leukemia: A case report
by: Marcela Espinoza, et al.
Published: (2023-05-01)

Post-mortem neuropathologic examination of a 6-case series of CAR T-cell treated patients
by: Núria Vidal Robau, et al.
Published: (2022-01-01)

Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia
by: Yue Tan, et al.
Published: (2023-04-01)

Peripheral blood cellular profile at pre-lymphodepletion is associated with CD19-targeted CAR-T cell-associated neurotoxicity
by: Serena De Matteis, et al.
Published: (2023-01-01)

Improved efficacy with early tocilizumab in the prophylaxis and treatment of cytokine release syndrome of chimeric antigen receptor T cell (CAR-T) therapy for diffuse large B-cell lymphoma than acute lymphoblastic leukemia
by: Chengxin Luan, et al.
Published: (2023-09-01)

HLA‐matched allogeneic anti‐CD19 CAR‐T therapy in treating a relapsed/refractory acute lymphoblastic leukemia patient with high tumor burden
by: Yue Huang, et al.
Published: (2022-06-01)

A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia
by: Massimo Martino, et al.
Published: (2021-02-01)

Neuropsychiatric disorders in adults undergoing chimeric antigen receptor T cells therapy for aggressive lymphomas and acute lymphoblastic leukemia
by: Josephine Emole, et al.
Published: (2023-01-01)

Efficacy and Safety of Chimeric Antigen Receptor T Cells in Acute Lymphoblastic Leukemia With Post-Transplant Relapse
by: Lijuan Ding, et al.
Published: (2021-11-01)

Mesothelin-targeted CAR-T cells for adoptive cell therapy of solid tumors
by: Gui-Zhen Zhang, et al.
Published: (2019-05-01)

Haploidentical CD7 CAR T-cells induced remission in a patient with TP53 mutated relapsed and refractory early T-cell precursor lymphoblastic leukemia/lymphoma
by: Hai-ping Dai, et al.
Published: (2022-02-01)

CAR T cell therapy becomes CHIC: “cytokine help intensified CAR” T cells
by: Simone Thomas, et al.
Published: (2023-01-01)

In Silico Structural Prediction and Production of a Chimeric Recombinant Dickkopf-1 (DKK-1) Antigen
by: Fatemeh Malaei, et al.
Published: (2019-06-01)